Mortality | N (%) | SF36 vitality score quartile | p-valuea | |||
---|---|---|---|---|---|---|
76–100 | 65–75 | 50–64 | 0–49 | |||
Model A: unadjusted full dataset HR (95 % CI) | 4397/18,101 (24.3 %) | 928/4395 (21.1 %) | 1103/5047 (21.9 %) | 1154/4501 (25.6 %) | 1212/4158 (29.1 %) | <0.001 |
1 (reference) | 1.04 (0.96–1.14) | 1.27 (1.17–1.39) | 1.49 (1.36–1.62) | |||
Model B: unadjusted with removal of baseline CVD/cancer HR (95 % CI) | 3637/16,409 (22.2 %) | 825/4097 (20.1 %) | 945/4657 (20.3 %) | 944/4049 (23.3 %) | 923/3606 (25.6 %) | <0.001 |
1 (reference) | 1.01 (0.92–1.11) | 1.20 (1.10–1.32) | 1.34 (1.22–1.47) | |||
Model C: confounders HR (95 % CI) | 3388/15,577 (21.8 %) | 771/3899 (19.8 %) | 886/4442 (19.9 %) | 880/3837 (22.9 %) | 851/3399 (25.0 %) | <0.001 |
1 (reference) | 1.02 (0.93–1.13) | 1.21 (1.10–1.34) | 1.40 (1.25–1.56) | |||
Model D: confounders + Hb HR (95 % CI) | 3388/15,577 (21.8 %) | 771/3899 (19.8 %) | 886/4442 (19.9 %) | 880/3837 (22.9 %) | 851/3399 (25.0 %) | <0.001 |
1(reference) | 1.01 (0.91–1.13) | 1.24 (1.12–1.39) | 1.40 (1.24–1.58) | |||
Model E: confounders + TSH HR (95 % CI) | 3388/15,577 (21.8 %) | 771/3899 (19.8 %) | 886/4442 (19.9 %) | 880/3837 (22.9 %) | 851/3399 (25.0 %) | <0.001 |
1 (reference) | 0.97 (0.86–1.09) | 1.23 (1.09–1.39) | 1.26 (1.10–1.45) | |||
Model F: confounders + CRP HR (95 % CI) | 3388/15,577 (21.8 %) | 771/3899 (19.8 %) | 886/4442 (19.9 %) | 880/3837 (22.9 %) | 851/3399 (25.0 %) | <0.001 |
1 (reference) | 1.06 (0.94–1.19) | 1.24 (1.10–1.40) | 1.39 (1.21–1.60) | |||
Model G: confounders + Hb, CRP, TSH HR (95 % CI) | 3388/15,577 (21.8 %) | 771/3899 (19.8 %) | 886/4442 (19.9 %) | 880/3837 (22.9 %) | 851/3399 (25.0 %) | 0.001 |
1 (reference) | 1.00 (0.87–1.15) | 1.26 (1.09–1.46) | 1.24 (1.05–1.46) |